company background image
HARP logo

Harpoon Therapeutics NasdaqCM:HARP Stock Report

Last Price

US$23.01

Market Cap

US$492.3m

7D

0.2%

1Y

243.4%

Updated

11 Mar, 2024

Data

Company Financials +

Harpoon Therapeutics, Inc.

NasdaqCM:HARP Stock Report

Market Cap: US$492.3m

HARP Stock Overview

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States.

HARP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Harpoon Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Harpoon Therapeutics
Historical stock prices
Current Share PriceUS$23.01
52 Week HighUS$23.21
52 Week LowUS$3.11
Beta2.1
1 Month Change2.49%
3 Month Change162.97%
1 Year Change243.43%
3 Year Change-88.71%
5 Year Change-81.26%
Change since IPO-82.96%

Recent News & Updates

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Jan 30
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Recent updates

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Jan 30
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Oct 01
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Aug 14
Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

May 28
Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Mar 11
Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Harpoon Therapeutics appoints Luke Walker as CMO

Oct 04

Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player

Sep 01

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Jul 30
Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Jul 07

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Mar 08
Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Nov 30
We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Harpoon Therapeutics: A First Look

Sep 16

Harpoon shares slide after early-stage prostate cancer study data fails to impress

Jun 04

Shareholder Returns

HARPUS BiotechsUS Market
7D0.2%0.9%0.4%
1Y243.4%10.3%28.8%

Return vs Industry: HARP exceeded the US Biotechs industry which returned 16% over the past year.

Return vs Market: HARP exceeded the US Market which returned 31% over the past year.

Price Volatility

Is HARP's price volatile compared to industry and market?
HARP volatility
HARP Average Weekly Movement32.6%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: HARP's share price has been volatile over the past 3 months.

Volatility Over Time: HARP's weekly volatility has increased from 21% to 33% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201553Julie Eastlandhttps://www.harpoontx.com

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications.

Harpoon Therapeutics, Inc. Fundamentals Summary

How do Harpoon Therapeutics's earnings and revenue compare to its market cap?
HARP fundamental statistics
Market capUS$492.35m
Earnings (TTM)-US$30.50m
Revenue (TTM)US$37.34m

13.2x

P/S Ratio

-16.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HARP income statement (TTM)
RevenueUS$37.34m
Cost of RevenueUS$58.63m
Gross Profit-US$21.29m
Other ExpensesUS$9.21m
Earnings-US$30.50m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.43
Gross Margin-57.02%
Net Profit Margin-81.67%
Debt/Equity Ratio194.4%

How did HARP perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.